Pfizer Corporation

Other

USA As Represented by Secretary of the Navy

Nimbus Wadjet, Inc.

US Government As Represented by the Secretary of the Army

Pfizer Products Inc.

Robert L Dow

David Andrew Griffith

Paul W Proctor

Philip Albert Carpino

Mary Theresa Didiuk

David Hepworth

Bradley Paul Morgan

Yuan-Ching Phoebe Chiang

Kevin K Liu

Andrew Gordon Swick

David W Piotrowski

Ariamala Gopalsamy

Scott William Bagley

Stephen Wayne Wright

Aaron Smith

Ralph Pelton Robinson, Jr

Shawn Cabral

Mihir D Parikh

Chulho Choi

Hatice Gizem Yayla

Jayasankar Jasti

Ming Zhu Chen

Olugbeminiyi Omezia Fadeyi

Steven R Schneider

Arjun Venkat Narayanan

Justin Andrew Caravella

Kevin Koch

Roger B Ruggeri

Derun Li

Matthew Scott Dowling

Angela V West

Lee Richard Roberts

Silvana Marcel Leit De Moradei

Lyn Howard Jones

Joseph Scott Warmus

Marlys Hammond

Agustin Casimiro-Garcia

Daniel Wei-Shung Kung

Matthew Forrest Sammons

Kimberly G Estep

Edward L Conn

Suvi Orr

Nathan E Genung

Florian Bartels

Benjamin N Rocke

Yan Zhang

Nikolay Sitnikov

Steven Wayne Goldstein

Michael John Munchhof

Bernard Hulin

Gary R Schulte

Keith Michael DeVries

David James Edmonds

David A Clark

Kristin M Lundy

James Alfred Southers, Jr

David K Kreutter

Ernest S Paight

Bonnie F Tate

Philip S Kornblum

Jay S Lief

David B Priser

Katherine L Kennedy

Agustin Casimiro Garcia

Peter Cornelius

Aaron Christopher Smith

Niall Stephen Doherty

The present disclosure is directed to compounds of Formula I: and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.

WRN inhibitors

The present disclosure is directed to compounds of Formula II-e: and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.

The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).

Chemical compounds

The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, Rand Rare as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).

The invention provides a compound of Formula (1) or a pharmaceutically acceptable salt of the compound, wherein R, R, R, Z, A, L and Aare as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R, R, R, Z, A, L and Aare as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.

2-thiopyrimidinones

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; whereinG is R, Rand Rare as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

N1/N2-lactam acetyl-CoA carboxylase inhibitors

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein 

The invention provides a compound of Formula (I) Z N N O N O A1R2 R1 R3R 3 L A2 (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3,Z, A1, L and A 5 2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal. 

Growing community of inventors

Waterford, CT, United States of America

Robert L Dow